AstraZeneca Annual Report and Form 20-F Information 2011

Development Pipelineat 31 December 2011Throughout the development process, we strive to obtain patent protection consistent with our patent process (as described in the IntellectualProperty section from page 34). However, until marketing approval in individual countries is obtained, it is not possible to accurately predict themaximum period of product protection available from any such patents. While the most significant uncertainties for development pipelineproducts progressing to launch are meeting development targets and obtaining regulatory marketing approvals (as detailed in the Risk sectionfrom page 129), the date and language of any actual marketing approval will crucially determine the length of Patent Term Extension and the fullrange, if any, of pending patents that will protect the marketed product. Further details of possible periods of patent, RDP and related IPprotections which may protect pipeline products once marketed are included on page 35.Line ExtensionsDateEstimated FilingCompound Mechanism Area Under Investigation PhaseCommencedPhaseUS EU Japan EmergingCardiovascularAxanumproton pump inhibitor + low low dose aspirin associated III Withdrawn Launched 1H 2013 Fileddose aspirin FDCpeptic ulcer in high risk CVpatientsBrilinta/ADP receptor antagonist outcomes study III 4Q 2010 2014 2014 2014 2014Brilique PEGASUS-TIMICrestor # statin outcomes in subjects withelevated CRPIII Launched Launched Fileddapagliflozin/metforminFDC #SGLT2 inhibitor + metforminFDCdiabetes III 3Q 2007 3Q 2012dapagliflozin # SGLT2 inhibitor diabetes – add on to DPP-IV III 1Q 2010 3Q 2012dapagliflozin # SGLT2 inhibitor diabetes – add on to insulin and III 2Q 2008 3Q 2012add on to metformin LT datadapagliflozin # SGLT2 inhibitor diabetes – in patients with high III 1Q 2013 3Q 2013CV risk – Study 18 and 19 dataKombiglyze XR TM / DPP-IV inhibitor + metformin diabetes III Launched Approved ApprovedKomboglyze TM FDC # * FDCOnglyza TMDPP-IV inhibitor outcomes study III 2Q 2010 2016 2016 2016SAVOR-TIMI #GastrointestinalEntocort glucocorticoid steroid Crohn’s disease and ulcerative III Launched Launched 2014 TBCcolitisNexium proton pump inhibitor peptic ulcer bleeding III Filed** Launched LaunchedNexium proton pump inhibitor GERD III Launched Launched Launched LaunchedInfectionFluMist/Fluenzlive, attenuated, intranasal influenza III Launched Approved Launchedinfluenza virus vaccineNeuroscienceDiprivan # sedative and anaesthetic conscious sedation III Launched 2H 2013 LaunchedEMLA # local anaesthetic topical anaesthesia III Launched Approved LaunchedOncologyFaslodex oestrogen receptor antagonist high dose (500mg) 2nd line III Launched Launched Launched Launchedadvanced breast cancerFaslodex oestrogen receptor antagonist 1st line advanced breast cancer III 2016 2016 2016 2016Iressa EGFR tyrosine kinase inhibitor 1st line EGFR mut+ NSCLC III Launched Launched LaunchedIressa EGFR tyrosine kinase inhibitor treatment beyond progression III 2015 2015 2015Respiratory & InflammationOxis long-acting ß 2 agonist COPD III Launched FiledSymbicortSymbicortSymbicortinhaled steroid/long-actingß 2 agonistinhaled steroid/long-actingß 2 agonistinhaled steroid/long-actingß 2 agonistasthma/III 1H 2013COPDCOPD III Launched Launched Filed LaunchedSMART III Launched Filed Launched# Partnered product.* Kombiglyze XR TM US; Komboglyze TM FDC EU.** 2nd CRL received in June 2011.Additional InformationAstraZeneca Annual Report and Form 20-F Information 2011Development Pipeline 199